Merck’s glorious victory in lung cancer marks a Russian winter for Bristol-Myers
Sunday was checkpoint inhibitor day at ESMO, with the three big players now in the market outlining how they’re lining up in the blockbuster field of lung cancer therapy. Merck was left in the enviable position of driving home some impressive results from its clinical study while Bristol-Myers Squibb had to try to put its miserable outcomes in a somewhat positive context and a determined Roche/Genentech team angled in on its niche.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.